Developments in HIV neuropathogenesis

Jeffrey A. Rumbaugh, Avindra Nath

Research output: Contribution to journalArticle

Abstract

Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.

Original languageEnglish (US)
Pages (from-to)1023-1044
Number of pages22
JournalCurrent Pharmaceutical Design
Volume12
Issue number9
DOIs
StatePublished - Mar 2006

Fingerprint

Virus Diseases
HIV
Knowledge Bases
Highly Active Antiretroviral Therapy
Viral Proteins
Developed Countries
Nervous System
Neurons
Therapeutics
Research

Keywords

  • Blood brain barrier
  • Cytokines
  • gp120
  • HAART
  • HIV dementia
  • MMP
  • Tat
  • TNF

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Developments in HIV neuropathogenesis. / Rumbaugh, Jeffrey A.; Nath, Avindra.

In: Current Pharmaceutical Design, Vol. 12, No. 9, 03.2006, p. 1023-1044.

Research output: Contribution to journalArticle

Rumbaugh, Jeffrey A. ; Nath, Avindra. / Developments in HIV neuropathogenesis. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 9. pp. 1023-1044.
@article{1e890964101946dd86ada5f46ff65029,
title = "Developments in HIV neuropathogenesis",
abstract = "Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.",
keywords = "Blood brain barrier, Cytokines, gp120, HAART, HIV dementia, MMP, Tat, TNF",
author = "Rumbaugh, {Jeffrey A.} and Avindra Nath",
year = "2006",
month = "3",
doi = "10.2174/138161206776055877",
language = "English (US)",
volume = "12",
pages = "1023--1044",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Developments in HIV neuropathogenesis

AU - Rumbaugh, Jeffrey A.

AU - Nath, Avindra

PY - 2006/3

Y1 - 2006/3

N2 - Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.

AB - Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.

KW - Blood brain barrier

KW - Cytokines

KW - gp120

KW - HAART

KW - HIV dementia

KW - MMP

KW - Tat

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=33645579949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645579949&partnerID=8YFLogxK

U2 - 10.2174/138161206776055877

DO - 10.2174/138161206776055877

M3 - Article

VL - 12

SP - 1023

EP - 1044

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 9

ER -